{"filings":[{"id":298470,"accession_number":"0001213900-23-047493","cik":1611747,"company_name":"Scinai Immunotherapeutics Ltd.","ticker":"SCNI","form_type":"8-K","filed_at":"2023-06-08T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"BiondVax enters exclusive worldwide license for IL-17 NanoAbs from Max Planck and UMG","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive worldwide license to develop and commercialize VHH antibodies (NanoAbs) targeting IL-17 for all indications.","Within 45 days of June 4, 2023, BiondVax will issue 17,000 American Depositary Shares to licensors, with a 1-year lock-up.","Milestone payments due upon IND submission and clinical study initiations; royalties on net sales apply.","BiondVax must submit an IND by June 30, 2025, or face termination by December 31, 2026, unless extended via EUR 500,000 payments.","Plans to initiate a preclinical in vivo efficacy study in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1553418.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298469,"accession_number":"0001213900-23-038612","cik":1611747,"company_name":"Scinai Immunotherapeutics Ltd.","ticker":"SCNI","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director George H. Lowell resigns from BiondVax board, stays on Scientific Advisory Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Resignation from Board effective May 12, 2023; served since 2008.","Resignation not due to any disagreement with the Company's operations, policies, or practices.","Will remain on Scientific Advisory Board and serve as liaison between Advisory Board and Board.","Compensation for continuing role and liaison duties currently under discussion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1553418.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298468,"accession_number":"0001213900-23-036435","cik":1611747,"company_name":"Scinai Immunotherapeutics Ltd.","ticker":"SCNI","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"BiondVax receives Nasdaq deficiency notice for minimum equity; deficit of $1.76M vs $2.5M required","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' deficit of $1.76M as of Dec 31, 2022, below Nasdaq's $2.5M minimum equity requirement.","Company has until June 15, 2023 to submit a plan to regain compliance with Nasdaq Capital Market.","If plan accepted, Nasdaq may grant up to 180-day extension; if rejected, company can appeal.","No immediate effect on trading of ADSs under symbol BVXV."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1553418.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298467,"accession_number":"0001213900-23-036129","cik":1611747,"company_name":"Scinai Immunotherapeutics Ltd.","ticker":"SCNI","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BiondVax publishes investor presentation on May 4, 2023; no financial results disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation made available on company website and discussed in meetings starting May 4, 2023.","Forward-looking statements reference NanoAbs pipeline, manufacturing facility, and potential collaborations.","No new financial guidance, earnings, or material operational updates were provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1553418.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}